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Effect of chemical modifications on allergenic potency of
peanut proteins
Ramon Bencharitiwong, Ph.D.,1 Hanneke P.M. van der Kleij, Ph.D.,2 Stef J. Koppelman, Ph.D.,2
and Anna Nowak-We˛grzyn, M.D.1
ABSTRACT
Background: Modification of native peanut extracts could reduce adverse effects of peanut immunotherapy.
Objective: We sought to compare native and chemically modified crude peanut extract (CPE) and major peanut allergens
Ara h 2 and Ara h 6 in a mediator-release assay based on the rat basophilic leukemia (RBL) cell line transfected with human
Fc receptor.
Methods: Native Ara h 2/6 was reduced and alkylated (RA), with or without additional glutaraldehyde treatment (RAGA).
CPE was reduced and alkylated. Sera of subjects with peanut allergy (16 males; median age 7 years) were used for overnight
RBL-passive sensitization. Cells were stimulated with 0.1 pg/mL to 10 g/mL of peanut. -N-acetylhexosaminidase
release (NHR) was used as a marker of RBL degranulation, expressed as a percentage of total degranulation caused by
Triton X.
Results: Median peanut-specific immunoglobulin E was 233 kUA/L. Nineteen subjects were responders, NHR  10% in
the mediator release assay. Responders had reduced NHR by RA and RAGA compared with the native Ara h 2/6. Modification
resulted in a later onset of activation by 10- to 100-fold in concentration and a lowering of the maximum release. Modified
RA-Ara h 2/6 and RAGA-Ara h 2/6 caused significantly lower maximum mediator release than native Ara h 2/6, at protein
concentrations 0.1, 1, and 10 ng/mL (p  0.001,  0.001, and  0.001, respectively, for RA; and  0.001, 0.026, and 0.041,
respectively, for RAGA). RA-CPE caused significantly lower maximum NHR than native CPE, at protein concentration 1
ng/mL (p  0.001) and 10 ng/mL (p  0.002). Responders had high rAra h 2 immunoglobulin E (mean, 61.1 kUA/L; p 
0.001) and higher NHR in mediator release assay to native Ara h 2/6 than CPE, which indicates that Ara h 2/6 were the most
relevant peanut allergens in these responders.
Conclusions: Chemical modification of purified native Ara h 2 and Ara h 6 reduced mediator release in an in vitro assay
100-fold, which indicates decreased allergenicity for further development of the alternative candidate for safe peanut
immunotherapy.
(Allergy Asthma Proc 36:185–191, 2015; doi: 10.2500/aap.2015.36.3840)
Peanut allergy affects 1% of young children in thedeveloped countries.1 Peanut is the major cause
of severe and fatal food-induced anaphylaxis.2,3 Cur-
rently, there is no cure for peanut allergy.4 Prior stud-
ies demonstrated efficacy of subcutaneous peanut im-
munotherapy with crude peanut extract (CPE),
however, with an unacceptable rate of serious adverse
reactions.5 Therefore, novel approaches for peanut im-
munotherapy are desirable.6–9 Chemical modification
could represent an effective strategy for adverse effect
reduction in peanut immunotherapy.
In the United States, immunoglobulin (Ig) E antibod-
ies to Ara h 1 and to Ara h 2 and its homolog, Ara h 6,
were most often detected in subjects who were 90–
100% peanut reactive, and were associated with in-
creased risk for anaphylaxis, which indicates high
allergenic potential in vivo.10–13 A novel approach to
creating a hypoallergenic preparation of Ara h 2 and
Ara h 6 involves chemical modification that results in
low IgE binding and preserved immunogenicity.14
These chemical modifications reduced the IgE-binding
100-fold in solid-phase immunoassays without re-
ducing T-cell immunogenicity.15
An important question is whether the reduction of
IgE-binding observed in solid-phase IgE-binding as-
says, such as the UniCAP system (Thermo Fisher Sci-
entific, Portage, MI) and enzyme-linked immunosor-
bent assay, is functionally relevant. We sought to
investigate the allergenicity of native and chemically
modified CPE and the purified mix of Ara h 2 and Ara
h 6 (Ara h 2/6) by using the in vitro mediator-release
assay and passively sensitized with IgE antibodies
from individuals with peanut allergy. The rat baso-
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philic leukemia (RBL) cell line transfected with human
FcRI receptor were used because of their documented
high affinity of human IgE binding and the ability to
detect allergens at very low concentrations, which
might not be detected in less-sensitive biochemical and
immunochemical assays.16–20
Furthermore, the mediator-release assay can be per-
formed with sera selected for optimal performance in a
wide range of protein concentrations and experimental
batch testing, and can be stored frozen for prolonged
periods of time, which results in more cost-effective-
ness and less variability than in the basophil activation
test based on the donor basophils.
Findings
Subjects
Sera were obtained from 26 subjects with a convinc-
ing history of peanut allergy (16 males; median age 7
years, 25–75% interquartile range, 5.5–10) (Table 1).
Subjects were recruited from the pediatric allergy prac-
tice at the Jaffe Food Allergy Institute. The study was
Figure 1. (A and B) Allergenic potency and dose-response curve of NHR (%) between native Ara h 2/6 and its modified form, RA-Arah
2/6, and (C and D) CPE and its modified form. The dilution that gives the ED50 was calculated. The reciprocal value of ED50 (1/ED) was
defined as the allergenic potency of the extract (1.E) and compared between native extract and its modified form on a logarithmic scale. Lines
connect the symbols that represent the allergenic potency of native and RA-Ara h 2/6 extracts from the sera of the same individual subject.
The overlapping number of subjects is shown. One responder (subject no. 12) was excluded because no NHR was induced by the RA-Ara
h 2/6 extract. Allergenic potency of RAGA-Ara h 2/6 extract was not shown due to the unreliability of the allergenic potency from very low
NHR (%). (A) Allergenic potency of native Ara h 2/6 and its modified form, RA-Ara h 2/6 in 19 responders. (B) Dose-response curve of NHR
induced by native Ara h 2/6 and its modified forms, RA-and RAGA-Ara h 2/6 in four representative responders. The curves represent NHR
(%) from the lowest peanut protein concentration (0.1 pg/mL, left) to the highest protein concentration (10 g/mL, right). (C) Allergenic
potency of CPE and its modified form, RA-CPE in 19 responders. Lines connect the symbols that represent the allergenic potency of CPE
and RA-CPE extracts from the sera of the same individual subject. The overlapping number of subjects was shown. One responder (subject
no. 12) was excluded due to no NHR induced by the RA-CPE extract. (D) A dose-response curves of NHR induced by CPE and its modified
form, RA-CPE in four representative responders; the curves represent NHR (%) from the lowest peanut protein concentration (0.1 pg/mL,
left) to the highest protein concentration (10 g/mL, right).
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approved by the Icahn School of Medicine at Mount
Sinai Institutional Review Board, and informed con-
sent was obtained.
MATERIALS AND METHODS
CPE was prepared from defatted peanut (Virginia
variety) flour and was subsequently reduced and alky-
lated (RA-CPE).14 CPE was prepared from defatted
peanut flour (Virginia-type peanuts) and was subse-
quently reduced and alkylated (RA-CPE) by reducing
the disulfide bonds and alkylating the resulting free
cysteines. Ara h 2/6 was purified as published,7 and
two forms of chemically modified Ara h 2/6 were
prepared (RA-Ara h 2/6, as described for RA-CPE),
and reduction and alkylation in combination with ad-
ditional cross-linking by glutaraldehyde (RAGA-Ara
h 2/6).14
A mediator-release assay was performed as previ-
ously described.19 Sera from the subjects with peanut
allergy were used for an overnight passive sensitiza-
tion of RBL cell lines. A serum pool made from equal
parts of 10 individual sera of responders (sera: 1, 6, 7,
10, 11, 13, 15, 16, 17, and 19) (Table E1) with high
peanut-, rAra h 1–, and rAra h 2–specific IgE antibody
levels (mean, 352.9, 149.1, and 156.8 kUA/L, respec-
tively) was used to optimize the peanut protein con-
centration range and serum dilution (1:20 and 1:40).
Thereafter, RBL cells were stimulated with allergenic
extracts at 10-fold dilutions from 0.1 pg/mL to 10
g/mL and with serum dilution at 1:40 in triplicates.
The extracts were used without a freeze-thaw cycle
more than twice to avoid proteins refolding. Peanut
allergen–induced NHR in the supernatant was used as
a marker of RBL degranulation. Rabbit IgG antihuman
polyclonal IgE (Bethyl Laboratories, Inc, Montgomery,
TX) was used as a positive control.13 Results were
expressed as the percentage of release from cells sen-
sitized with individual serum minus spontaneous re-
lease (with buffer), which was then divided by total
release with 1% Triton X-100 (Sigma-Aldrich, St. Louis,
MO) as follows:
% NHR  ([release by allergen – spontaneous re-
lease]/release by Triton X)  100%
The dilution that gave the half maximal release was
calculated (ED50). The reciprocal value of ED50 (1/ED)
was defined as the allergenic potency of the extract
compared between native peanut extract and its mod-
ified form.
Nineteen responders were arbitrarily defined as
those whose sera produced maximum NHR  10% to
CPE or native Ara h 2/6 at 1–10 ng/mL concentration.
Peanut-, rAra h 2-specific IgE (sIgE), rAra h 2-sIgE/
total IgE ratio, and peanut-sIgE/total IgE ratio mea-
sured by UniCAP system were significantly higher in
responders than in nonresponders (Table 1).
Table 2. Allergenic potency reduction of
chemically modified RA-Ara h 2/6 extract
Responder
No.
Potency of
Native
Ara h 2/6
Potency of RA-Ara
h 2/6 Relative to
the Potency of
Native Ara H 2/6
1 100 10
2 100 1
3 100 100
4 100 100
5 100 0.01
6 100 100
7 100 10
8 100 10
9 100 10
10 100 0.001
11 100 100
12 100 0
13 100 0.00001
14 100 0.00001
15 100 0.00001
16 100 10
17 100 10
18 100 0.001
19 100 100
Table 3. Allergenic potency reduction of
chemically modified RA-CPE extract
Responder
No.
Potency of
Native
CPE
Potency of RA-CPE
Relative to the Potency
of Native CPE
1 100 100
2 100 10
3 100 10
4 100 10
5 100 0.1
6 100 10
7 100 10
8 100 10
9 100 10
10 100 10
11 100 10
12 100 0
13 100 0.01
14 100 0.1
15 100 0.1
16 100 10
17 100 10
18 100 1
19 100 100
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RESULTS
The calculated allergenic potency and NHR dose-
response curve of native extract and its modified form
are shown in Fig. 1. Fig. 1, A and B represent native Ara
h 2/6 and RA-Ara h 2/6; Fig. 1, C and D represent CPE
and RA-CPE. NHR induced by chemically modified
extracts was reduced compared with their native coun-
terparts. (Tables 2 and 3) Chemical modification re-
sulted in an onset of activation at a higher allergen
concentration by 10-to 100-fold as well as in a lowering
of the maximum NHR. Modified RA-Ara h 2/6 and
RAGA-Ara h 2/6 caused significantly lower maximum
mediator release than native Ara h 2/6 at protein con-
centration 0.1, 1, and 10 ng/mL (p  0.001, p  0.001,
p  0.001, respectively, for RA; and at p  0.001, 0.026,
and 0.041, respectively, for RAGA) (Table 4). RA-CPE
caused significantly lower maximum NHR than native
CPE at protein concentrations 1 ng/mL (p 0.001) and
10 ng/mL (p  0.002) (Table 4). There was a significant
positive correlation between rAra h 2-specific IgE and
the maximum NHR induced by native and chemically
modified peanut extracts (Table 5). Responders had
high rAra h 2 IgE (mean, 61.1 kUA/L; p  0.001) and
had higher NHR in mediator release assay to native
Ara h 2/6 than CPE (data not shown), which indicates
that Ara h 2/6 was the most relevant peanut allergen in
these responders. IgE antibody levels and mediator
release were positively correlated and associated with
responder status.19 We observed a similar association
(Table 5).
DISCUSSION
We demonstrated that chemical modification of pea-
nut resulted in100-fold reduction in mediator release
in an in vitro assay, which indicates a significantly
decreased allergenicity. This is in line with observa-
tions made for modified Ara h 2/6 when using a
solid-phase IgE-binding assay and findings of a recent
study performed in European adult subjects.15
We focused on conglutin storage Ara h 2 due to its
high allergenic potency and resistance to digestive pro-
teases pepsin and trypsin. In addition, Ara h 6 has a
high homology of amino acid sequence to Ara h 2,
especially in the middle part and at the C-terminal part
of the protein from peanut. Koppelman et al.21 showed
the cross-reactivity in IgE binding of purified Ara h 6
and Ara h 2 described as potent allergens in peanut.
Vissers et al.22 reported that heat-induced conformation
of native Ara h 2/6 purified after roasting retained its
native forms and that extensively heat-induced dena-
turation did not affect the allergenicity properties of
Ara h 2/6 from roasted peanut. Thus, a chemical pro-
tein modification strategy could be used as an alterna-
tive approach to destroy allergenic peptide epitopes
with maintained immunogenicity.
Table 4. Peanut allergen-induced NHR with 19 responder sera
Responders, n  19 Native Peanut Extract NHR,
% (median 25–75% IQR)
Modified Peanut Extract NHR, %
(median 25–75% IQR)
p Value
At the maximum release
CPE 15.1 (7.2–26.8) RA-CPE 12.2 (3.5–24.2) 0.189*
Ara h 2/6 18.5 (11.5–31.9) RA-Ara h 2/6 5.2 (2.2–19.3) 0.001
RAGA-Ara h 2/6 9 (2.7–16.5) 0.001
At 0.1 ng/mL
CPE 1.7 (0.2–2.5) RA-CPE 0.2 (0–1) 0.079*
Ara h 2/6 10.9 (8.2–17.5) RA-Ara h 2/6 0.7 (0–3.9)  0.001#
RAGA-Ara h 2/6 2.4 (0.6–4.4)  0.001#
At 1 ng/mL
CPE 7.6 (2.6–12.9) RA-CPE 0.8 (0.2–4.0)  0.001#
Ara h 2/6 15.7 (9.3–31.9) RA-Ara h 2/6 1.2 (0.4–9.0)  0.001#
RAGA-Ara h 2/6 3.5 (0.7–9.0)  0.001#
At 10 ng/mL
CPE 15.1 (7.2–25.9) RA-CPE 3 (1–11.4) 0.002
Ara h 2/6 13.9 (3.5–28.6) RA-Ara h 2/6 4.4 (1–17.8) 0.026
RAGA-Ara h 2/6 4.5 (2.1–13.1) 0.041
*p  not statistically significant, #p  0.05 was considered statistically significant, (SigmaStat 3.5, Mann-Whitney rank sum
t-test).
IQR  interquartile range.
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We found that chemical modification of crude pea-
nut and purified native Ara h 2/6 reduced mediator
release in an in vitro mediator-release assay 100-fold,
which indicates decreased allergenicity. Furthermore,
it can be performed with sera selected for optimal
performance in a wide range of protein concentrations
and experimental batch testing, and can be stored fro-
zen for prolonged periods of time, which results in
more cost-effectiveness and less variability of basophil
activation test from donors. We observed that some
nonresponder sera with high-specific IgE to peanut
and rAra h 2 induced a low mediator release, NHR 
10%. This low release might be explained by lower IgE
antibody affinity, a lower number of recognized IgE-
binding epitopes, or dilution effect, in the presence of
high total IgE antibodies.
CONCLUSIONS
The confirmation of the decreased IgE binding of
chemically modified native peanut proteins is an im-
portant step for the further development of the alter-
native candidate for safe and successful peanut immu-
notherapy. However, the wide range of the individual
responses to chemically modified peanut proteins war-
rants caution and indicates that, before immunother-
apy with chemically modified peanut proteins, careful
patient characterization and selection must be consid-
ered.
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